Symbols / GPCR Stock $44.76 -1.65% Structure Therapeutics Inc.

Healthcare • Biotechnology • United States • NGM
GPCR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Raymond C. Stevens Ph.D.
Exch · Country NGM · United States
Market Cap 3.18B
Enterprise Value 1.78B
Income -170.34M
Sales —
FCF (ttm) -104.20M
Book/sh 20.36
Cash/sh 20.52
Employees 233
Insider 10d —
IPO Feb 03, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -23.53
PEG —
P/S —
P/B 2.20
P/C —
EV/EBITDA -8.18
EV/Sales —
Quick Ratio 25.59
Current Ratio 26.16
Debt/Eq 0.40
LT Debt/Eq —
EPS (ttm) -2.64
EPS next Y -1.90
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -11.57%
ROE -15.00%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 71.07M
Shs Float 54.91M
Insider Own 2.66%
Instit Own 96.01%
Short Float 10.75%
Short Ratio 7.27
Short Interest 5.57M
52W High 94.90
vs 52W High -52.83%
52W Low 15.80
vs 52W Low 183.29%
Beta -1.42
Impl. Vol. 68.87%
Rel Volume 0.81
Avg Volume 867.94K
Volume 699.22K
Target (mean) $104.59
Tgt Median $101.00
Tgt Low $69.50
Tgt High $145.00
# Analysts 16
Recom Strong_buy
Prev Close $45.51
Price $44.76
Change -1.65%
About

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$104.59
Mean price target
2. Current target
$44.76
Latest analyst target
3. DCF / Fair value
$-26.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$44.76
Low
$69.50
High
$145.00
Mean
$104.59

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-11 main HC Wainwright & Co. Buy → Buy $70
2026-04-27 init Canaccord Genuity — → Buy $101
2026-03-16 main HC Wainwright & Co. Buy → Buy $100
2026-03-02 main HC Wainwright & Co. Buy → Buy $114
2026-02-27 main Citizens Market Outperform → Market Outperform $113
2026-01-22 main JP Morgan Overweight → Overweight $105
2026-01-20 main Guggenheim Buy → Buy $140
2025-12-19 main HC Wainwright & Co. Buy → Buy $90
2025-12-12 main Morgan Stanley Overweight → Overweight $125
2025-12-12 main Citizens Market Outperform → Market Outperform $120
2025-12-11 main Jefferies Buy → Buy $125
2025-12-09 main Citigroup Buy → Buy $100
2025-12-09 main Stifel Buy → Buy $90
2025-12-09 main Clear Street Buy → Buy $99
2025-08-07 main HC Wainwright & Co. Buy → Buy $60
2025-08-07 main Guggenheim Buy → Buy $90
2025-08-07 main JMP Securities Market Outperform → Market Outperform $87
2025-06-23 reit Cantor Fitzgerald Overweight → Overweight $65
2025-06-23 reit JMP Securities Market Outperform → Market Outperform $89
2025-05-12 main HC Wainwright & Co. Buy → Buy $75
News
RSS: Latest GPCR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-15 LANG MATTHEW Chief Operating Officer — 184,614 $0.00 $0
2026-03-19 STEVENS RAYMOND C Chief Executive Officer — 260,217 $0.00 $0
2026-03-19 HALL ASHLEY Officer — 47,706 $0.00 $0
2026-03-19 MA YINGLI Chief Technology Officer — 32,526 $0.00 $0
2026-03-19 LIN XICHEN Officer — 43,368 $0.00 $0
2026-03-19 YOON JUN Chief Financial Officer — 104,085 $0.00 $0
2026-03-19 COLL CRESPO BLAS Officer — 75,897 $0.00 $0
2025-07-01 STEVENS RAYMOND C Chief Executive Officer — 89,697 $0.00 $0
2025-07-01 MA YINGLI Chief Technology Officer — 24,459 $0.00 $0
2025-07-01 LIN XICHEN Officer — 57,078 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
186.81
+18.06%
158.23
+53.96%
102.78
+95.53%
52.56
Research And Development
225.25
+107.01%
108.81
+55.22%
70.10
+93.69%
36.19
Selling General And Administration
61.55
+24.57%
49.41
+51.24%
32.67
+99.61%
16.37
General And Administrative Expense
61.55
+24.57%
49.41
+51.24%
32.67
+99.61%
16.37
Other Gand A
61.55
+24.57%
49.41
+51.24%
32.67
+99.61%
16.37
Other Operating Expenses
-100.00
—
—
—
Total Expenses
186.81
+18.06%
158.23
+53.96%
102.78
+95.53%
52.56
Operating Income
-186.81
-18.06%
-158.23
-53.96%
-102.78
-95.53%
-52.56
Total Operating Income As Reported
-176.56
-11.59%
-158.23
-53.96%
-102.78
-95.53%
-52.56
EBITDA
-185.48
-17.96%
-157.24
-53.43%
-102.48
-96.01%
-52.28
Normalized EBITDA
-195.72
-24.48%
-157.24
-53.43%
-102.48
-96.01%
-52.28
Reconciled Depreciation
1.33
+34.38%
0.99
+236.27%
0.29
+6.50%
0.28
EBIT
-186.81
-18.06%
-158.23
-53.96%
-102.78
-95.53%
-52.56
Total Unusual Items
10.25
0.00
0.00
—
Total Unusual Items Excluding Goodwill
10.25
0.00
0.00
—
Special Income Charges
10.25
0.00
0.00
—
Net Income
-141.20
-15.24%
-122.53
-36.72%
-89.62
-74.63%
-51.32
Pretax Income
-140.69
-15.11%
-122.22
-36.73%
-89.38
-74.22%
-51.30
Net Non Operating Interest Income Expense
35.87
-0.39%
36.01
+168.93%
13.39
+965.31%
1.26
Net Interest Income
35.87
-0.39%
36.01
+168.93%
13.39
+965.31%
1.26
Other Income Expense
10.25
—
—
—
Tax Provision
0.52
+66.13%
0.31
+31.36%
0.24
+1288.24%
0.02
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
2.15
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-141.20
-15.24%
-122.53
-36.72%
-89.62
-74.63%
-51.32
Net Income From Continuing Operation Net Minority Interest
-141.20
-15.24%
-122.53
-36.72%
-89.62
-74.63%
-51.32
Net Income From Continuing And Discontinued Operation
-141.20
-15.24%
-122.53
-36.72%
-89.62
-74.63%
-51.32
Net Income Continuous Operations
-141.20
-15.24%
-122.53
-36.72%
-89.62
-74.63%
-51.32
Minority Interests
—
—
—
0.00
Normalized Income
-149.30
-21.85%
-122.53
-36.72%
-89.62
-74.63%
-51.32
Net Income Common Stockholders
-141.20
-15.24%
-122.53
-36.72%
-89.62
-69.62%
-52.84
Otherunder Preferred Stock Dividend
—
—
0.00
-100.00%
1.51
Diluted EPS
-1.99
+6.80%
-2.14
+11.98%
-2.43
-75.89%
-1.38
Basic EPS
-1.99
+6.80%
-2.14
+11.98%
-2.43
-75.89%
-1.38
Basic Average Shares
70.84
+23.65%
57.29
+55.96%
36.73
-3.95%
38.24
Diluted Average Shares
70.84
+23.65%
57.29
+55.96%
36.73
-3.95%
38.24
Diluted NI Availto Com Stockholders
-141.20
-15.24%
-122.53
-36.72%
-89.62
-69.62%
-52.84
Gain On Sale Of PPE
10.25
0.00
0.00
—
Net Income From Tax Loss Carryforward
—
—
—
—
Preferred Stock Dividends
—
—
—
1.51
Total Other Finance Cost
-35.87
+0.39%
-36.01
-168.93%
-13.39
-965.31%
-1.26
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,583.92
+75.34%
903.33
+87.41%
482.02
+392.63%
97.84
Current Assets
1,570.30
+76.20%
891.21
+88.17%
473.61
+408.77%
93.09
Cash Cash Equivalents And Short Term Investments
1,446.20
+63.69%
883.52
+89.06%
467.32
+414.44%
90.84
Cash And Cash Equivalents
799.62
+371.73%
169.51
+30.60%
129.79
+397.46%
26.09
Other Short Term Investments
646.57
-9.44%
714.01
+111.54%
337.53
+421.28%
64.75
Receivables
100.00
0.00
—
—
Other Receivables
100.00
—
—
—
Prepaid Assets
—
—
—
—
Other Current Assets
24.11
+213.35%
7.69
+22.40%
6.29
+179.58%
2.25
Total Non Current Assets
13.62
+12.34%
12.12
+44.12%
8.41
+76.81%
4.76
Net PPE
12.90
+83.92%
7.01
-16.15%
8.36
+546.87%
1.29
Gross PPE
15.87
+83.45%
8.65
-3.99%
9.01
+448.60%
1.64
Accumulated Depreciation
-2.97
-81.48%
-1.64
-154.04%
-0.64
-84.53%
-0.35
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.50
+101.21%
0.75
+35.14%
0.55
+219.08%
0.17
Construction In Progress
1.28
0.00
—
—
Other Properties
11.55
+76.56%
6.54
-7.79%
7.10
+421.76%
1.36
Leases
1.54
+12.94%
1.36
+0.00%
1.36
+1147.71%
0.11
Other Non Current Assets
0.72
-85.96%
5.11
+11246.67%
0.04
-98.70%
3.46
Total Liabilities Net Minority Interest
67.54
+75.49%
38.49
+32.48%
29.05
-86.36%
212.99
Current Liabilities
63.28
+75.69%
36.02
+45.60%
24.74
+90.16%
13.01
Payables And Accrued Expenses
47.97
+77.46%
27.03
+42.47%
18.98
+106.12%
9.21
Payables
13.86
+72.78%
8.02
+69.21%
4.74
-23.31%
6.18
Accounts Payable
13.86
+72.78%
8.02
+69.21%
4.74
-21.09%
6.01
Other Payable
—
—
—
—
Current Accrued Expenses
34.11
+79.44%
19.01
+33.56%
14.23
+370.82%
3.02
Pensionand Other Post Retirement Benefit Plans Current
12.43
+70.56%
7.29
+68.55%
4.33
+22.04%
3.54
Total Tax Payable
—
—
0.36
+104.60%
0.17
Income Tax Payable
—
—
0.36
+104.60%
0.17
Current Debt And Capital Lease Obligation
2.88
+69.49%
1.70
+17.92%
1.44
+453.85%
0.26
Current Capital Lease Obligation
2.88
+69.49%
1.70
+17.92%
1.44
+453.85%
0.26
Total Non Current Liabilities Net Minority Interest
4.26
+72.59%
2.47
-42.80%
4.31
-97.84%
199.97
Long Term Debt And Capital Lease Obligation
3.61
+66.77%
2.16
-46.08%
4.01
0.00
Long Term Capital Lease Obligation
3.61
+66.77%
2.16
-46.08%
4.01
0.00
Other Non Current Liabilities
0.65
+114.24%
0.30
+1.34%
0.30
—
Preferred Securities Outside Stock Equity
—
0.00
0.00
-100.00%
199.97
Stockholders Equity
1,516.38
+75.34%
864.84
+90.93%
452.97
+493.40%
-115.14
Common Stock Equity
1,516.38
+75.34%
864.84
+90.93%
452.97
+493.40%
-115.14
Capital Stock
0.02
+23.53%
0.02
+21.43%
0.01
+1300.00%
0.00
Common Stock
0.02
+23.53%
0.02
+21.43%
0.01
+1300.00%
0.00
Preferred Stock
—
0.00
0.00
0.00
Share Issued
212.51
+23.65%
171.86
+23.44%
139.22
+21.35%
114.73
Ordinary Shares Number
212.51
+23.65%
171.86
+23.44%
139.22
+21.35%
114.73
Additional Paid In Capital
1,985.60
+66.44%
1,193.01
+81.03%
659.00
+34205.21%
1.92
Retained Earnings
-470.30
-42.91%
-329.10
-59.31%
-206.57
-76.63%
-116.95
Gains Losses Not Affecting Retained Earnings
1.05
+15.32%
0.91
+75.43%
0.52
+573.64%
-0.11
Other Equity Adjustments
1.05
+15.32%
0.91
+75.43%
0.52
+573.64%
-0.11
Total Equity Gross Minority Interest
1,516.38
+75.34%
864.84
+90.93%
452.97
+493.40%
-115.14
Total Capitalization
1,516.38
+75.34%
864.84
+90.93%
452.97
+493.40%
-115.14
Working Capital
1,507.02
+76.22%
855.19
+90.52%
448.87
+460.53%
80.08
Invested Capital
1,516.38
+75.34%
864.84
+90.93%
452.97
+493.40%
-115.14
Total Debt
6.49
+67.97%
3.86
-29.18%
5.45
+1997.31%
0.26
Capital Lease Obligations
6.49
+67.97%
3.86
-29.18%
5.45
+1997.31%
0.26
Net Tangible Assets
1,516.38
+75.34%
864.84
+90.93%
452.97
+493.40%
-115.14
Tangible Book Value
1,516.38
+75.34%
864.84
+90.93%
452.97
+493.40%
-115.14
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-222.20
-90.51%
-116.64
-46.73%
-79.49
-72.35%
-46.12
Cash Flow From Continuing Operating Activities
-222.20
-90.51%
-116.64
-46.73%
-79.49
-72.35%
-46.12
Net Income From Continuing Operations
-141.20
-15.24%
-122.53
-36.72%
-89.62
-74.63%
-51.32
Depreciation Amortization Depletion
1.33
+34.38%
0.99
+236.27%
0.29
+6.50%
0.28
Depreciation
1.33
+34.38%
0.99
+236.27%
0.29
+6.50%
0.28
Depreciation And Amortization
1.33
+34.38%
0.99
+236.27%
0.29
+6.50%
0.28
Other Non Cash Items
2.56
+59.25%
1.60
+145.04%
0.66
+88.76%
0.35
Stock Based Compensation
28.99
+54.26%
18.79
+129.45%
8.19
+225.82%
2.51
Operating Gains Losses
-10.25
—
—
—
Gain Loss On Investment Securities
-10.25
—
—
—
Change In Working Capital
-88.04
-3070.34%
2.96
-57.45%
6.97
+134.70%
2.97
Change In Receivables
-100.00
0.00
0.00
—
Change In Prepaid Assets
-16.41
-1065.70%
-1.41
+65.12%
-4.04
-1223.61%
-0.30
Change In Payables And Accrued Expense
26.28
+138.38%
11.02
-2.47%
11.30
+205.98%
3.69
Change In Accrued Expense
21.51
+178.79%
7.72
-36.55%
12.16
+689.29%
1.54
Change In Payable
4.76
+44.09%
3.31
+484.53%
-0.86
-139.94%
2.15
Change In Account Payable
4.76
+44.09%
3.31
+484.53%
-0.86
-139.94%
2.15
Change In Other Current Assets
4.39
+186.72%
-5.06
-33840.00%
0.01
+125.00%
-0.06
Change In Other Current Liabilities
-2.30
-44.31%
-1.59
-405.08%
-0.32
+12.74%
-0.36
Investing Cash Flow
89.80
+125.02%
-358.91
-33.75%
-268.34
-332.06%
-62.11
Cash Flow From Continuing Investing Activities
89.80
+125.02%
-358.91
-33.75%
-268.34
-332.06%
-62.11
Net PPE Purchase And Sale
-3.61
-180.16%
-1.29
+40.47%
-2.17
-1298.06%
-0.15
Purchase Of PPE
-3.61
-180.16%
-1.29
+40.47%
-2.17
-1298.06%
-0.15
Capital Expenditure
-3.61
-180.16%
-1.29
+40.47%
-2.17
-1298.06%
-0.15
Net Investment Purchase And Sale
93.41
+126.12%
-357.62
-34.35%
-266.18
-329.64%
-61.95
Purchase Of Investment
-547.38
+22.08%
-702.52
-68.33%
-417.36
-238.07%
-123.45
Sale Of Investment
640.79
+85.79%
344.90
+128.14%
151.18
+145.82%
61.50
Financing Cash Flow
762.52
+47.99%
515.26
+14.11%
451.53
+1456.25%
29.01
Cash Flow From Continuing Financing Activities
762.52
+47.99%
515.26
+14.11%
451.53
+1456.25%
29.01
Net Common Stock Issuance
665.71
+29.37%
514.57
+8.95%
472.30
0.00
Proceeds From Stock Option Exercised
99.45
+3900.24%
2.49
+210.75%
0.80
+2324.24%
0.03
Net Other Financing Charges
-2.64
-46.88%
-1.80
+91.67%
-21.57
-756.09%
-2.52
Changes In Cash
630.11
+1486.47%
39.72
-61.70%
103.70
+230.91%
-79.21
Beginning Cash Position
169.51
+30.60%
129.79
+397.46%
26.09
-75.22%
105.31
End Cash Position
799.62
+371.73%
169.51
+30.60%
129.79
+397.46%
26.09
Free Cash Flow
-225.81
-91.49%
-117.93
-44.42%
-81.66
-76.46%
-46.27
Amortization Of Securities
-15.59
+15.59%
-18.46
-209.04%
-5.97
-560.22%
-0.91
Common Stock Issuance
665.71
+29.37%
514.57
+8.95%
472.30
0.00
Issuance Of Capital Stock
665.71
+29.37%
514.57
+8.95%
472.30
+1399.35%
31.50
Net Preferred Stock Issuance
—
—
0.00
-100.00%
31.50
Preferred Stock Issuance
—
—
0.00
-100.00%
31.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category